Status:
UNKNOWN
Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Influences After Botulinum Neurotoxin Type A Injection
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
Cerebral Palsy
Eligibility:
All Genders
5-18 years
Brief Summary
Botulinum neurotoxin type A (BoNT-A) intervention to control the hypertonia of muscles is one of the evidence-based managements for children with spastic cerebral palsy. However, BoNT-A injection in a...
Detailed Description
Individuals with cerebral palsy is vulnerable to osteopenia and sarcopenia. Botulinum neurotoxin type A (BoNT-A) intervention to control the hypertonia of muscles is one of the evidence-based manageme...
Eligibility Criteria
Inclusion
- diagnosis of spastic CP (cerebral palsy)
- moderate to severe spasticity over the limbs, Modified Ashworth Scale score≧2
Exclusion
- fixed contractures of the limbs
- previous musculoskeletal surgery on the limbs
- contraindications to botulinum toxin intervention
Key Trial Info
Start Date :
September 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05207124
Start Date
September 2 2020
End Date
July 1 2025
Last Update
September 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital
Tainan, Taiwan, 138